Skip to Content

Roche Holding AG ADR RHHBY Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 34.52
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 34.34  –  34.56
  • Year Range 34.34  –  43.32
  • Market Cap 220.3640 Bil
  • Volume / Avg 387,117.0 /  1.5 Mil
  • Price / Sales 3.39
  • Price / Book 7.48
  • Forward Div Yield 3.33%
  • Trailing Div Yield 3.71%

Morningstar‘s Stock Analysis RHHBY

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Roche's Pharmaceutical and Diagnostics Arms Work Together To Support a Wide Moat

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics RHHBY

Company Profile RHHBY

Business Description

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Grenzacherstrasse 124
Basel, 4070, CHE
Industry Drug Manufacturers - General
Employees 103,613

Related Articles RHHBY

Competitors & Peers RHHBY

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of RHHBY’s competitive advantage.

Roche Holding AG ADR


Merck & Co Inc


Regeneron Pharmaceuticals Inc


AbbVie Inc

−$0.03 (0.10%) −$0.13 (0.12%) +$5.19 (0.63%) +$0.15 (0.10%)
Market Cap
220.36 Bil270.53 Bil89.94 Bil271.09 Bil
Drug Manufacturers - General Drug Manufacturers - General Biotechnology Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Roche Holding AG ADR Stock

Yes. RHHBY has a forward dividend yield of 3.71%. See RHHBY’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

RHHBY’s market cap is 220.36 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

RHHBY’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

RHHBY’s price/sales is 3.39.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

RHHBY’s price/forward earnings is 18.93.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

RHHBY’s price/book is 7.48.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See RHHBY’s valuation ratios compared to the Market Index.

RHHBY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare RHHBY’s historical performance against its industry peers and the overall market.